Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth (NASDAQ:CSTL)

Castle Biosciences (CSTL) delivered a material guidance raise to $365M–$375M for 2026, signaling accelerating adoption of its core diagnostic platform. The TissueCypher product line's trajectory toward 50%–52% growth represents operational leverage and validates the company's dermatology-oncology positioning within precision medicine. This guidance beat implies management confidence in both volume expansion and pricing resilience in a competitive diagnostics market.

The 20% Q2 revenue growth establishes a foundation for sustained momentum, though the reported risks around margins and average selling price (ASP) warrant monitoring. Diagnostics firms often face pricing pressure from payers and consolidators; CSTL's ability to maintain or expand ASPs while scaling TissueCypher volumes will be critical to converting guidance into earnings accretion. Early-stage margin expansion could reverse if reimbursement headwinds intensify.

Investor interest in precision medicine and cancer-related diagnostics remains elevated, particularly as personalized treatment pathways gain clinical adoption. CSTL's narrow, focused portfolio reduces diversification risk but concentrates execution risk on TissueCypher uptake and reimbursement stability. The guidance raise itself is a positive signal, yet sustainability depends on execution against these volume and pricing assumptions.

Sector implication: Health Care sector gains modest tailwind from this earnings-driven pop, though the move is predominantly company-specific. Precision diagnostics remain a structural growth area, but investors should differentiate between guidance beats and durable competitive moats in a consolidating industry.